Navigation Links
Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
Date:9/15/2009

SOUTH SAN FRANCISCO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that 320 evaluable events (patient deaths) have occurred in its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial, which is being conducted in accordance with a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), evaluating picoplatin in the treatment of small cell lung cancer (SCLC).

"The 320th event in our pivotal registration SPEAR trial was defined in our SPA with the FDA to enable the Company to begin final analysis of data. Our goal is to complete and report the results of our preliminary analysis in the fourth quarter of 2009 and, if positive, initiate the rolling New Drug Application filing process for picoplatin by year-end under the Fast Track designation previously granted by the FDA," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "The SPA helps ensure that the design and clinical endpoints of our randomized trial and our planned analysis of the study are aligned with the FDA to support submission of an NDA."

SPEAR Trial Design

The international, multi-center, randomized, controlled Phase 3 SPEAR trial is evaluating the efficacy and safety of picoplatin as second-line therapy in 401 cancer patients with SCLC who have not responded to or who relapsed following first-line platinum-based therapy. The primary endpoint of the trial is overall survival. The Statistical Analysis Plan of the trial, as agreed to in the SPA, is 90 percent powered to show a 33 percent reduction in risk in overall survival for picoplatin treatment with best supportive care (BSC) compared with BSC alone (hazard ratio of 0.67; p<0.05). The trial completed enrollment
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 01, 2014 “2014 Deep ... Resin Industry” is a professional and in-depth ... report introduces Polyurethane Resin basic information, including ... structure and industry overview. This research covers ... market as well as global industry analysis ...
(Date:7/31/2014)... over 60 are not donor candidates for bone marrow ... making the elderly prone to life-threatening infection and other ... has discovered a reason why. , "We have found ... cells to maintain blood production over time in an ... be restored for rejuvenation therapies," said Emmanuelle Passegu, PhD, ...
(Date:7/31/2014)... the sound-processing part of the mouse brain in a ... trees in view. Their imaging technique allows zooming in ... and it enabled the team to watch brain cells ... results, which represent a step toward better understanding how ... the journal Neuron . , In the past, ...
(Date:7/31/2014)... , July 31, 2014 According ... Research "Quantum Dots Market - Global Industry Analysis, Size, ... market was valued at USD 88.5 million in 2011, ... 2023, growing at a CAGR of 53.8% from 2013 ... Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html Increasing demand ...
Breaking Biology Technology:Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4Key to aging immune system is discovered 2New mapping approach lets scientists zoom in and out as the brain processes sound 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4
... N.Y., Sept. 5 BioSpecifics,Technologies Corp. (OTC Bulletin ... collagenase based products, announced today that,it has signed ... related,to its future royalty obligations for Peyronie,s disease ... one-time cash payment., BioSpecifics has modified its ...
... 4 Hologic, Inc.,(Nasdaq: HOLX ) today announced ... the Morgan Stanley Global Healthcare Unplugged,Conference being held September ... NY., Interested parties are invited to listen to ... September 9, 2008, at 1:35 PM.,Eastern Time on the ...
... COLLINS, Colo., Sept. 4 InVitria,( ... of animal free,products that enhance productivity, ... companies,in the biopharmaceutical, cell culture, life ... Sponsorship of Cambridge Healthtech,Institute,s 4th Annual ...
Cached Biology Technology:BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease 2Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference 2
(Date:7/31/2014)... have completed a 20-year study that looks at ... different times of the year. It finds that ... frame has no measurable negative consequences for the ... , The study was conducted by Gene Towne, ... fire chief, and Joseph Craine, research assistant professor, ...
(Date:7/31/2014)... experimental vaccine protected 100 percent of animal models against ... , which causes an intestinal disease that kills approximately ... print in Infection and Immunity . , ... non-human primates against the purified toxins produced by ... spore infection, a laboratory model that mimics the human ...
(Date:7/31/2014)... Edmond Becquerel first discovered the photovoltaic effect in 1839, ... power of sunlight for its own purposes. In a ... of the FASEB Journal , scientists ... power of sunlight by focusing on a naturally occurring ... evolution. This conservationor persistence over time and across speciessuggests ...
Breaking Biology News(10 mins):Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists shine bright new light on how living things capture energy from the sun 2
... that previously unrecognized substances released by algae blooms have ... interfere with the normal activity of reproductive hormones. The ... as potentially harmful to humans and aquatic animals, but ... are calling for a revision of environmental monitoring programs ...
... the establishment of the Jeffrey Modell Endowed Chair in ... at the Hospital,s Ruth and Tristram Colket, Jr. Translational ... pediatric immunologist Jordan S. Orange, M.D., Ph.D. The chair,s ... new ground in his ongoing research. Dr. Orange is ...
... the brain are characteristic features of Alzheimer disease. The ... that plays a central role in learning and memory, ... effect of tau protein is largely eliminated when the ... Max Planck Research Unit for Structural Molecular Biology at ...
Cached Biology News:Modell Chair in Pediatric Immunology established 2Tau-induced memory loss in Alzheimer's mice is reversible 2Tau-induced memory loss in Alzheimer's mice is reversible 3
...
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by incubation of linoleic acid with ... to inhibit the adhesion of tumor cells to ...
...
...
Biology Products: